FFRCT Analysis
Diagnosis of hemodynamically significant coronary artery disease
ApprovedCommercial
Key Facts
Indication
Diagnosis of hemodynamically significant coronary artery disease
Phase
Approved
Status
Commercial
Company
About HeartFlow
HeartFlow's mission is to transform coronary artery disease (CAD) from the leading cause of death into a manageable condition for life. The company leverages a proprietary AI-powered platform to analyze CCTA scans, generating non-invasive fractional flow reserve (FFRCT) measurements, plaque quantification, and anatomical roadmaps to guide patient care. With over 600,000 patients treated, 1,800+ institutions using its technology, and a robust clinical evidence base of 600+ peer-reviewed publications, HeartFlow is establishing itself as a leader in precision cardiovascular diagnostics. The company is headquartered in San Francisco, California, and operates globally.
View full company profile